|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Pancreatic involvement in chronic viral hepatitis显示文摘AIM: To elucidate the frequency and characteristics of pancreatic disorders in the course of chronic viral hepatitis. METHODS: We prospectively assessed the serum pancreatic enzyme levels and imaging findings in patients with chronic viral hepatitis and healthy control subjects. RESULTS: Serum amylase (t-Amy), salivary amylase (s-Amy), pancreatic amylase (p-Amy) and serum lipase levels were higher in hepatitis patients in comparison to control subjects. However, in asymptomatic viral carriers, only the serum t-Amy levels were higher than those of the controls. The levels of each enzyme rose with the progression of liver disease in patients with hepatitis B or C; whereas the levels of each enzyme within the same clinical stage of the disease did not differ between patients diagnosed with either hepatitis B or hepatitis C virus. Imaging findings demonstrated chronic pancreatitis in only 1 out of 202 patients (0.5%).CONCLUSION: Our data suggest that serum levels of pancreatic enzymes increase with the progression of liver disease in patients diagnosed with viral hepatitis. Pancreatic disease, asymptomatic in most cases, may represent an extrahepatic manifestation of chronic viral hepatitis. | Yoshiki Katakura Hiroshi Yotsuyanagi Kiyoe Hashizume Chiaki Okuse Noriaki Okuse Kohji Nishikawa Michihiro Suzuki Shiro Iino Fumio Itoh | 2005 | World Journal of Gastroenterology2005，11，23： | 5 |
| 2 | Fatal liver failure caused by reactivation of lamivudine-resistant hepatitis B virus:A case report显示文摘We present a case of fetal liver failure caused by the activation of lamivudine-resistant hepatitis B virus (HBV) nine months after lamivudine treatment. A 57-year old man visited our hospital for the treatment of decompensated chronic hepatitis B. Lamivudine was started in December 2001. Subsequently, serum HBV was negative for HBV DNA with seroconversion from HBeAg to anti-HBe and improvement of liver function. However, HBV DNA and HBeAg were again detected in September 2002. He was complicated by breakthrough hepatitis and admitted to our hospital in November for severely impaired liver function. Vidarabine treatment was started and serum HBV DNA and alanine aminotransferase (ALT) decreased transiently. However, after the start of α-interferon treatment, HBV DNA level increased and liver function deteriorated. He died 1 mo after admission. An analysis of amino acid sequences in the polymerase region revealed that rtM204I/V with rtL80I/V occurred at the time of viral breakthrough. After the start of antiviral treatment, rtL180M was detected in addition to rtM204I/V and rtL80I/V, and became predominant in the terminal stage of the disease. HBV clone with a high replication capacity may be produced by antiviral treatment leading to the worsening of liver function. Antiviral therapy for patients with breakthrough hepatitis in advanced liver disease should be carefully performed. | Yuka Suzuki Hiroshi Yotsuyanagi Chiaki Okuse Yoshihiko Nagase Hideaki Takahashi Kyoji Moriya Michihiro Suzuki Kazuhiko Koike Shiro Iino Fumio Itoh | 2007 | World Journal of Gastroenterology2007，13，6： | 4 |
| 3 | Risk factors for retinopathy associated with interferonα-2b and ribavirin combination therapy in patients with chronic hepatitis C显示文摘AIM: To elucidate the frequency and risk factors for retinopathy in patients with chronic hepatitis C who are treated by interferon-ribavirin combination therapy. METHODS: We prospectively analyzed 73 patients with histologically confirmed chronic hepatitis C, who underwent combination therapy for 24 wk. Optic fundi were examined before, and 2, 4, 12 and 24 wk after the start of combination therapy. RESULTS: Fourteen patients (19%) developed retinopathy, which was initially diagnosed by the appearance of a cotton wool spot in 12 patients. Retinal hemorrhage was observed in 5 patients. No patient complained of visual disturbance. Retinopathy disappeared in 9 patients (64%) despite the continuation of combination therapy. However, retinopathy persisted in 5 patients with retinal hemorrhage. A comparison of the clinical background between the groups with and without retinopathy showed no significant differences in age, gender, viral genotype, RNA level, white blood cell count, platelet count, prothrombin time, complications by diabetes mellitus or hypertension, or pretreatment arteriosclerotic changes in the optic fundi. However, multiple logistic regression analysis revealed that complication by hypertension was observed with a high frequency in the group with retinopathy (P = 0.004, OR=245.918, 95% CI=5.6-10786.2). CONCLUSION: Retinopathy associated with combination therapy of interferon a-2b and ribavirin tends to develop in patients with hypertension. | Chiaki Okuse Hiroshi Yotsuyanagi Yoshihiko Nagase Yuhtaro Kobayashi Kiyomi Yasuda Kazuhiko Koike Shiro Iino Michihiro Suzuki Fumio Itoh | 2006 | World Journal of Gastroenterology2006，12，23： | 4 |
| 4 | Treatment of chronic hepatitis C with high-dose interferon α-2b显示文摘 | Shiro Iino MD Kunihiko Hino MD Tetsuo Kuroki MD Hiroshi Suzuki MD Sukeo Yamamoto MD | 1993 | Digestive Diseases and Sciences1993，，4： | 2 |
| 5 | Precore and core promoter mutations, hepatitis B virus DNA levels and progressive liver injury in chronic hepatitis B显示文摘 | Hiroshi Yotsuyanagi Kunihiko Hino Eiichi Tomita Joji Toyoda Kiyomi Yasuda Shiro Iino | 2002 | Journal of Hepatology2002，，3： | 2 |
| 6 | A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C显示文摘 | Etsuro Orito Masashi Mizokami Hiroshi Sakugawa Kojiro Michitaka Kazuyoshi Ishikawa Takafumi Ichida Takeshi Okanoue Hiroshi Yotsuyanagi Shiro Iino | 2001 | Hepatology2001，，1： | 2 |
| 7 | Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients显示文摘 | Akihiro Matsumoto Eiji Tanaka Akinori Rokuhara Kendo Kiyosawa Hiromitsu Kumada Masao Omata Kiwamu Okita Norio Hayashi Takeshi Okanoue Shiro Iino Kyuichi Tanikawa | 2005 | Hepatology Research2005，，3： | 1 |
| 8 | Therapeutic effects of stronger neo-minophager C at diffenet doses on chronic hepatitis and liver cirrhosis显示文摘 | Toshiro Tango Takashi Matsushima | 2001 | Hepatology Research2001，19，： | 1 |
| 9 | Hepatitis B virus genotypes and hepatocellular carcinoma in Japan显示文摘 | Hajime Fujie Kyoji Moriya Yoshizumi Shintani Hiroshi Yotsuyanagi Shiro Iino Satoshi Kimura Kazuhiko Koike | 2001 | Gastroenterology2001，，6： | 1 |
| 10 | Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients显示文摘 | Akihiro Matsumoto Eiji Tanaka Akinori Rokuhara Kendo Kiyosawa Hiromitsu Kumada Masao Omata Kiwamu Okita Norio Hayashi Takeshi Okanoue Shiro Iino Kyuichi Tanikawa | 2005 | Hepatology Research2005，，3： | 1 |
| 11 | Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients显示文摘 | Akihiro Matsumoto Eiji Tanaka Akinori Rokuhara Kendo Kiyosawa Hiromitsu Kumada Masao Omata Kiwamu Okita Norio Hayashi Takeshi Okanoue Shiro Iino Kyuichi Tanikawa | 2005 | Hepatology Research2005，，3： | 1 |
| 12 | Serum lipid profile of patients with genotype 1b hepatitis C viral infection in Japan显示文摘 | Kyoji Moriya Yoshizumi Shintani Hajime Fujie Hideyuki Miyoshi Takeya Tsutsumi Hiroshi Yotsuyanagi Shiro Iino Satoshi Kimura Kazuhiko Koike | 2002 | Hepatology Research2002，，4： | 1 |
| 13 | Therapeutic effects of stronger neo- minophager C at different doses on chronic hepatitis and liver cirrhosis 显示文摘 | Shiro Iino Toshiro Tango Takashi Matsushima | 2001 | Hepatology Research2001，19，： | 1 |
| 14 | Therapeutic ef-feets of cirrhosis显示文摘 | Shiro Iino Toshiro Tango Takashi Matsushima | 2001 | H epatology Research2001，19，： | 1 |
| 15 | Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients显示文摘 | Akihiro Matsumoto Eiji Tanaka Akinori Rokuhara Kendo Kiyosawa Hiromitsu Kumada Masao Omata Kiwamu Okita Norio Hayashi Takeshi Okanoue Shiro Iino Kyuichi Tanikawa | 2005 | Hepatology Research2005，，3： | 1 |
| 16 | A significant reduction in serum alanine aminotransferase levels after 3-month iron reduction therapy for chronic hepatitis C: a multicenter, prospective, randomized, controlled trial in Japan显示文摘 | Motoyoshi Yano Hisao Hayashi Kentaro Yoshioka Yutaka Kohgo Hiroyuki Saito Yoshiro Niitsu Junji Kato Shiro Iino Hiroshi Yotsuyanagi Yoshimasa Kobayashi Kinya Kawamura Shinichi Kakumu Masahiko Kaito Jiro Ikoma Shinya Wakusawa Takeshi Okanoue Yoshio Sumida F | 2004 | Journal of Gastroenterology2004，，6： | 1 |
| 17 | Therapeutic effects of Stronger Neo- Minophagen C at different doses on chronic hepatitis and liver cirrhosis显示文摘 | Shiro Iino Toshiro Tango Takashi Matsushima | 2001 | Hepatology Ressearch2001，19，： | 1 |
| 18 | Therapeutic effetcts of stronger neo-minophager C at different doses on chronic hepatits and liver cirrhosis显示文摘 | Shiro Iino Toshiro Tango Takashi Matsushima | 2001 | Hepatology Research2001，19，31： | 1 |
| 19 | Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients显示文摘 | Akihiro Matsumoto Eiji Tanaka Akinori Rokuhara Kendo Kiyosawa Hiromitsu Kumada Masao Omata Kiwamu Okita Norio Hayashi Takeshi Okanoue Shiro Iino Kyuichi Tanikawa | 2005 | Hepatology Research2005，，3： | 1 |
| 20 | Precore and core promoter mutations, hepatitis B virus DNA levels and progressive liver injury in chronic hepatitis B显示文摘 | Hiroshi Yotsuyanagi Kunihiko Hino Eiichi Tomita Joji Toyoda Kiyomi Yasuda Shiro Iino | 2002 | Journal of Hepatology2002，，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员